Open AccessTreatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
Author(s) -
Srinivas Annavarapu,
Anagha Gogate,
Thuy Thi Thu Pham,
Kalatu Davies,
Prianka Singh,
Nicholas J. Robert
Publication year - 2021
Publication title -
cns oncology
Language(s) - English
Resource type - Journals
eISSN - 2045-0915
pISSN - 2045-0907
DOI - 10.2217/cns-2021-0007
Subject(s) - temozolomide , medicine , methyltransferase , oncology , glioblastoma , o 6 methylguanine dna methyltransferase , methylation , radiation therapy , dna methylation , retrospective cohort study , cohort , cancer research , gene , biology , biochemistry , gene expression
Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O 6 -methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. Patients & methods: US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. Results: Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25.5 vs 12.4 months). Untested status, unmethylated MGMT and older age were associated with reduced OS and longer 1L treatment with increased OS. Similar findings were observed for progression-free survival. Utilization was similar between cohorts. Conclusion: In community oncology practices, MGMT methylation and testing were predictive of better survival in GBM.